TargetMol

FLLL32

Product Code:
 
TAR-T6838
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6838-2mg2mg£101.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6838-5mg5mg£119.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6838-1mL1 mL * 10 mM (in DMSO)£124.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6838-10mg10mg£139.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6838-25mg25mg£172.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6838-50mg50mg£237.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6838-100mg100mg£367.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6838-500mg500mg£781.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).
CAS:
1226895-15-3
Formula:
C28H32O6
Molecular Weight:
464.558
Pathway:
Apoptosis; Chromatin/Epigenetic; Stem Cells; Angiogenesis; JAK/STAT signaling
Purity:
0.998
SMILES:
COc1ccc(C=CC(=O)C2(CCCCC2)C(=O)C=Cc2ccc(OC)c(OC)c2)cc1OC
Target:
Apoptosis; JAK; STAT

References

Lin L, et al. Cancer Res. 2010, 70(6), 2445-2454. Lin L, et al. Mol Cancer. 2010, 9, 217. Wattenberg LW, et al. Invest New Drugs. 2012, 30(3, 916-926.